Abilify is the brand name of aripiprazole, an atypical antipsychotic and partial dopamine agonist.
Here’s a list of Abilify prices:
The drug was developed by a Japanese company, Otsuka, in 1988. For the United States market, Bristol-Myers Squibb markets it as a joint venture with Otsuka America.
Abilify is used primarily for the treatment of schizophrenia and bipolar disorder, as well as a secondary treatment in the management of tic disorders, depression, and autism-related irritability, among others. The dosage forms include intramuscular injection as a solution: long-acting intramuscular injections in both single-use syringes and lyophilized powder; oral solution; and tablet usually in crème de vanilla flavour.
The U.S. Food and Drug Administration (FDA) approved its use in its oral form for schizophrenic patients, particularly in the management of acute exacerbations and relapse prevention. It is also an effective drug in maintenance therapy for adults, adolescents and children with bipolar disorder. Emphasis must be made that its effectiveness only applies to the prevention and treatment of acute manic episodes.
Abilify is also effective albeit to a limited degree in the management of the symptoms in major depressive disorder, obsessive-compulsive disorder, and autism. Doctors must weigh the costs (i.e., side effects) and benefits (i.e., improvement in symptoms) before prescribing the drug.
In depression, the overall benefit to the patient ranges from small to moderate while the higher rate of side effects can reduce its overall efficacy. In autism, patients can show reduced signs of hyperactivity, irritability and stereotypy in the short-term period. In obsessive-compulsive disorder, a low dose may be effective in patients whose symptoms didn’t improve with the use of SSRIs alone.